10X Genomics Inc

자세한 내용은 10X Genomics Inc 회사

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

회사 정보

종목 코드 TXG

회사 이름10X Genomics Inc

상장일Sep 12, 2019

설립일2012

CEOMr. Serge Wilson Saxonov, Ph.D.

직원 수1306

유형Ordinary Share

회계 연도 종료Sep 12

주소6230 Stoneridge Mall Road

도시PLEASANTON

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호94588

전화19254017300

웹사이트https://www.10xgenomics.com/

종목 코드 TXG

상장일Sep 12, 2019

설립일2012

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Serge Wilson Saxonov, Ph.D.

Chief Executive Officer, Co-Founder, Director

1.07M

-0.09%

Dr. John R. Stuelpnagel

Independent Chairman of the Board

369.61K

+4.34%

Whitaker (Eric S)

Chief Legal Officer

202.20K

+29.09%

Mr. Sridhar (Sri) Kosaraju

Independent Director

59.45K

+34.83%

Dr. Benjamin J. Hindson, Ph.D.

President, Co-Founder, Chief Scientific Officer, Director

52.17K

-12.55%

Ms. Kimberly J. (Kim) Popovits

Independent Director

28.62K

+115.82%

Dr. Shehnaaz Suliman, M.D.

Independent Director

28.62K

+115.82%

Mr. Adam S. Taich

Chief Financial Officer

--

Mr. Alan V. Mateo

Independent Director

--

Dr. Sarah A. Teichmann

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Serge Wilson Saxonov, Ph.D.

Chief Executive Officer, Co-Founder, Director

1.07M

-0.09%

Dr. John R. Stuelpnagel

Independent Chairman of the Board

369.61K

+4.34%

Whitaker (Eric S)

Chief Legal Officer

202.20K

+29.09%

Mr. Sridhar (Sri) Kosaraju

Independent Director

59.45K

+34.83%

Dr. Benjamin J. Hindson, Ph.D.

President, Co-Founder, Chief Scientific Officer, Director

52.17K

-12.55%

Ms. Kimberly J. (Kim) Popovits

Independent Director

28.62K

+115.82%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Consumables

115.36M

74.48%

Products and services revenue

17.06M

11.01%

Instruments

14.81M

9.57%

Services

7.65M

4.94%

지역별USD

이름

수익

비율

United States

86.82M

56.05%

Europe, the Middle East and Africa

31.89M

20.59%

China

16.88M

10.90%

Asia Pacific

15.54M

10.03%

Americas

3.75M

2.42%

사업별

지역별

사업별USD

이름

수익

비율

Consumables

115.36M

74.48%

Products and services revenue

17.06M

11.01%

Instruments

14.81M

9.57%

Services

7.65M

4.94%

주식 보유 통계

마지막 업데이트: Fri, May 23

주주

주주 유형

주주

비율

ARK Investment Management LLC

11.56%

The Vanguard Group, Inc.

9.99%

Fidelity Management & Research Company LLC

7.72%

Millennium Management LLC

4.98%

BlackRock Institutional Trust Company, N.A.

4.87%

Other

60.88%

주주

비율

ARK Investment Management LLC

11.56%

The Vanguard Group, Inc.

9.99%

Fidelity Management & Research Company LLC

7.72%

Millennium Management LLC

4.98%

BlackRock Institutional Trust Company, N.A.

4.87%

Other

60.88%

주주 유형

주주

비율

Investment Advisor

45.04%

Investment Advisor/Hedge Fund

22.18%

Hedge Fund

19.03%

Bank and Trust

5.32%

Research Firm

5.16%

Venture Capital

3.69%

Individual Investor

1.92%

Pension Fund

0.68%

Family Office

0.30%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

656

115.46M

103.93%

-12.51M

2025Q1

687

115.67M

104.27%

-8.84M

2024Q4

689

107.08M

98.92%

-12.41M

2024Q3

682

106.90M

100.39%

-9.08M

2024Q2

691

105.36M

99.70%

-5.09M

2024Q1

762

106.36M

101.17%

-3.12M

2023Q4

817

100.80M

96.01%

-9.73M

2023Q3

835

96.86M

93.80%

-12.55M

2023Q2

857

94.98M

96.77%

-15.37M

2023Q1

864

95.62M

97.55%

-9.91M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

ARK Investment Management LLC

12.85M

11.56%

+901.66K

+7.55%

Mar 31, 2025

The Vanguard Group, Inc.

11.09M

9.99%

+184.54K

+1.69%

Mar 31, 2025

Fidelity Management & Research Company LLC

8.58M

7.72%

-2.75M

-24.30%

Mar 31, 2025

Millennium Management LLC

5.53M

4.98%

+156.13K

+2.90%

Apr 01, 2025

BlackRock Institutional Trust Company, N.A.

5.41M

4.87%

-108.37K

-1.96%

Mar 31, 2025

Sumitomo Mitsui Trust Bank, Limited

5.36M

4.83%

+5.36M

--

Mar 31, 2025

UBS Asset Management (Switzerland)

4.10M

3.69%

+2.13M

+108.14%

Mar 31, 2025

Two Sigma Investments, LP

3.17M

2.85%

+614.32K

+24.04%

Mar 31, 2025

UBS Asset Management (Americas) LLC

2.90M

2.61%

+2.85M

+4.95K%

Mar 31, 2025

BofA Global Research (US)

2.56M

2.3%

+2.03M

+386.97%

Mar 31, 2025

11.910USD

10X Genomics Inc

11.910

개요

회사